KR950701622A - 안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties) - Google Patents

안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties)

Info

Publication number
KR950701622A
KR950701622A KR1019940704151A KR19940704151A KR950701622A KR 950701622 A KR950701622 A KR 950701622A KR 1019940704151 A KR1019940704151 A KR 1019940704151A KR 19940704151 A KR19940704151 A KR 19940704151A KR 950701622 A KR950701622 A KR 950701622A
Authority
KR
South Korea
Prior art keywords
methoxy
tetrahydro
compound
phenylmethoxy
isoquinolinecarboxylic acid
Prior art date
Application number
KR1019940704151A
Other languages
English (en)
Inventor
클립톤 존 블랭클리
존 쿡 훗쥐
실베스터 클러치코
Original Assignee
로즈 암스트롱
워너-램버트 컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 워너-램버트 컴파니 filed Critical 로즈 암스트롱
Publication of KR950701622A publication Critical patent/KR950701622A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 혈관 재발성 협착증, 다양한 중추신경계질환 치료, 여성생식기 기능조절, 인식력증대, 아테롬성 동맥경화증치료 및 지나친 AVP 분비질환 치료에 유용한 신규의 1,2,3,4-테트라하이드로이소퀴놀린, 당해 화합물 제조에 유용한 중간체, 당해 화합물을 사용하는 방법, 당해 화합물을 함유하는 제약학적 조성물에 관한다.

Description

안기오텐신 Ⅱ 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN Ⅱ RECEPTOR ANTAGONIST-PROPERTIES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그의 제약학적으로 허용되는 염
    Ⅰ
    식중, R1과 R2는 각기 독립하여 수소, 저급알킬, 할로겐, 하이드록시, 알콕시, 아미노, 알킬아미노, 디알킬아미노, 아실아미노, CF3, 카복시, 카보알콕시, 하이드록시알킬, 아미노알킬 및 니트로; n은 0에서 4까지의 정수;X는 부재(absent), O, S, NH, N- 알킬이고, 5 또는 6위이체 존재하는 테트라하이드로이소퀴놀린에 부착됨; R3는 6,7 또는 8 위치에 부착되는 할로겐 또는 알킬티오, 아릴옥시, 알콕시, 수소; R4는 수소, 알킬, 하이드록시알킬, CO2R6, CON(R6)2(R6는 수소 또는 저급알킬임); 및 R5는 알킬/또는 아릴부분에 존재하는 비치환 또는 치환될 수 있는 아르알킬, 아릴, 알킬, 디아르알킬(아릴부분은 비치환 또는 치환될 수 있음), COR7, SO2R7(R7은 아르알킬, 알킬, 디아르알킬임), OR8, NR8R9(R8과 R9는 각기 독립하여 수소, 알킬, 사이클로알킬, 아릴 또는 아르알킬임).
  2. 제1항에 있어서, R1과 R2가 각기 독립하여 수소, 저급알킬, 알콕시, 아미노, 카복시 및 니트로; n가 0에서 3까지의 정수; X가 S, O 또는 NH; R3가 수소, 알콕시 또는 할로겐; R4가 수소, 알킬, 하이드록시알킬, CO2R6, CON(R6)2,; 및 R5가 알킬, 아릴, 또는 COR7이 되는 화합물.
  3. 제1항에 있어서, R1과 R2가 각기 독립하여 수소, 저급알킬, 알콕시, 카복시 및 니트로; n가 0에서 2까지의 정수; X가 0; R3가 알콕시; R4가 CO2R6, CON(R6)2; 및 R5가 COR7(R7은 디아르알킬) 또는 NR8R9(R8과 R9는 각기 독립하여 수소, 알킬, 또는 아릴)이 되는 화합물.
  4. 제1항에 있어서, R1과 R2가 각기 독립하여 수소, 메톡시, 카복시, 메틸, 니트로, 또는 아미노; n가 0, 1 또는 2; X가 0, NH 또는 NCH3; R3가 H, -SCH3, 또는 -OCH3; R4가 -COOH, COOCH3, COOC2H5, -CONH2, 및; R5가 수소,
    이 되는 화합물.
  5. 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5(페닐메톡시)-3-이소퀴놀린카복실산,2-(디페닐아세틸)-1,2,3,4-테트라하이드로-7-메톡시-6-(페닐메톡시)-3-이소퀴놀린카복실산, 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 2-(비스(4-클로로페닐)아세틸]-1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 2-(싸이클로펜틸 페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 2-[(2,6-디클로로페닐)아세틸]-1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-6-메톡시-2-[(메틸 페닐 아미노)카보닐]-5(페닐메톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-6-메톡시-2-[[(4-메톡시페닐)아미노]카보닐]-5(페닐메톡시)-3-이소퀴놀린카복실산, 2-[[(4-플로오로페닐)아미노]카보닐]-1,2,3,4-6-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 에스테르, 5-[(4-카보메톡시페닐)메톡시-2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-3-이소퀴놀린카복실산, 에틸에스테르, 5-(4-카복시페닐메톡시)-2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-3-이소퀴놀린카복실산, 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5-[(4-메톡시-3-메틸페닐)메톡시]-3-이소퀴놀린카복실산, 에틸에스테르, 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-5-[(4-메톡시-3-메틸페닐)메톡시]-3-이소키놀린카복실산, 2-(디디페닐아세틸)-1, 2, 3, 4-테트라하이드로-6-메톡시-5-(4-니트로페녹시)-3-이소퀴놀린카복실산, 메틸에스테르, 5-(4-아미노페녹시)-2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-3-이소퀴놀린카복실산, 메틸에스테르, 5-(4-아미노페녹시)-2-(디페닐아세틸)-1,2,3,4-테트라하이드로-6-메톡시-3-이소퀴놀린카복실산, 및 (+)-2-(디페닐아세틸)1,2,3,4-테드라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산에서 선택되는 화합물.
  6. 3-메톡시-2-(페닐메톡시)페닐알라닌, 4-메톡시-3-(페닐메톡시)페닐알라닌, 3-메톡시-2-(2-페닐에톡시)페닐알라닌, 3-메톡시-2-(4-니트로페녹시)페닐알라닌, 1, 2, 3, 4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-7-메톡시-6-(페닐메톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-6-메톡시-5-(2-페닐메톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-6-메톡시-5-(4-니트로페톡시)-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-5-하이드록시-6-메톡시-3-이소퀴놀린카복실산, 1,2,3,4-테트라하이드로-6-메톡시-5-(페닐메톡시)-3-이소퀴놀린카복실산, 에틸에스테르, 1,2,3,4-테트라하이드로-5-하이드록시-6-메톡시-3-이소퀴놀린카복실산, 에틸에스테르, 1,2,3,4-테트라하이드로-6-메톡시-5-(4-니트로페녹시)-3-이소퀴놀린카복실산, 메틸에스테르, N-아세틸-3-메톡시 2-(페닐메톡시)-페닐알라닌, 1,2,3,4-테트라하이드로-5-하이드록시-6-메톡시-2-[메틸(페닐아미노)카보닐]-3-이소퀴놀린 카복실산, 및 2-(디페닐아세틸)-1,2,3,4-테트라하이드로-5-하이드록시-6-메톡시-3-이소퀴놀린카복실산, 에틸에스테르에서 선택되는 화합물
  7. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 인식력 저하질환에 걸린 포유류의 인식력 저하치료용 제약학적 조성물.
  8. 치료적으로 효과적인 양의 제1항 화합물을 인식력 저하질환에 걸린 포유류에게 투여하는 것으로 구성되는 인식력 저하질환에 걸린 포유류의 인식력저하 치료방법.
  9. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 재발성협착증에 걸린 포유류의 재방성 협착증 치료용 제약학적 조성물.
  10. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 재발성협착증에 걸린 포유류의 재발성 협착증치료방법.
  11. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 아테톰성 동맥경화증에 걸린 포유류의 아테톰성 동맥경화증 치료용 제약학적 조성물.
  12. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 아테톰성 동맥경화증에 걸린 포유류의 아테톰성 동맥 경화증 치료방법.
  13. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 여성 생식기질환에 걸린 포유류의 여성생식기 질환치료용 제약학적 조성물.
  14. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 여성 생식기질환에 걸린 포유류의 여성생식기 질환치료 방법.
  15. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 우울증에 걸린 포유류의 우울증치료용 제약학적 조성물.
  16. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 우울증에 걸린 포유류의 우울중 치료방법.
  17. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 지나친 AVP 분비 관련질환에 걸린 포유류의 지나친 AVP 분비관련질환 치료용 제약학적 조성물.
  18. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 지나친 AVP 분비 관련질환에 걸린 포유류의 지나친 AVP 분비 관련질환 치료방법.
  19. 치료적으로 효과적인 양의 제1항 화합물을 제약학적으로 허용되는 캐리어와 함께 투여하는 것으로 구성되는 혈관 및 심장 비대증에 걸린 포유류의 혈관 및 심장 비대증 치료용 제약학적 조성물.
  20. 치료적으로 효과적인 양의 제1항 화합물을 투여하는 것으로 구성되는 혈관 및 심장 비대증에 걸린 포유류의 혈관 및 심장 비대증 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940704151A 1992-05-19 1993-04-19 안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties) KR950701622A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US885,263 1992-05-19
US07/885,263 US5246943A (en) 1992-05-19 1992-05-19 Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
PCT/US1993/003662 WO1993023378A1 (en) 1992-05-19 1993-04-19 Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ii receptor antagonist properties

Publications (1)

Publication Number Publication Date
KR950701622A true KR950701622A (ko) 1995-04-28

Family

ID=25386509

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704151A KR950701622A (ko) 1992-05-19 1993-04-19 안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties)

Country Status (14)

Country Link
US (4) US5246943A (ko)
EP (1) EP0641326A1 (ko)
JP (1) JPH07508266A (ko)
KR (1) KR950701622A (ko)
AU (2) AU671283B2 (ko)
CA (1) CA2134765A1 (ko)
CZ (1) CZ284177B6 (ko)
HU (1) HU217069B (ko)
MX (1) MX9302888A (ko)
NO (1) NO302071B1 (ko)
NZ (1) NZ252856A (ko)
RU (1) RU2135473C1 (ko)
SK (1) SK280677B6 (ko)
WO (1) WO1993023378A1 (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5409926A (en) * 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
ATE233734T1 (de) * 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
EP0925063A4 (en) 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
AU3513497A (en) * 1996-07-01 1998-01-21 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
US5912342A (en) * 1997-08-12 1999-06-15 Heinonen; Petri Compounds a containing a solid support
AU9512298A (en) * 1997-09-30 1999-04-23 Molecular Design International, Inc. Beta3-adrenoreceptor agonists, agonist compositions and methods of using
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
CN1215059C (zh) * 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
BR0209735A (pt) 2001-05-29 2004-07-27 Kyoto Pharma Ind Derivados heterocìclicos e uso medicinal destes
NZ530358A (en) * 2001-05-29 2005-04-29 Kyoto Pharma Ind Heterocyclic compound and medicinal use thereof
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DK1474395T3 (da) * 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamidderivater, der er nyttige som p38-inhibitorer
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
BR0316919A (pt) * 2002-12-02 2005-10-18 Pharmacia & Upjohn Co Llc Utilização de tetraidroisoquinolinas 4-fenil-substituìdas no tratamento da dor, cefaléias da enxaqueca e incontinência urinária
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
AU2005318882B2 (en) * 2004-12-24 2011-04-21 Novartis Ag Method of treatment or prophylaxis
EP1830869B1 (en) * 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
JP2008534504A (ja) * 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 月経前障害を治療するためのβラクタミルアルカン酸
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
JP6232184B2 (ja) 2010-01-19 2017-11-15 ノバルティス アーゲー 神経伝導速度改善のための方法および組成物
US9376424B2 (en) 2010-07-01 2016-06-28 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
HUE028620T2 (en) 2010-07-21 2016-12-28 Novartis Ag Tetrahydroisoquinoline derivative salt and solvates
EP2420237A1 (en) * 2010-08-11 2012-02-22 Ville Takio Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
WO2015003223A1 (en) 2013-07-08 2015-01-15 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods of their use
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106831573B (zh) * 2017-01-23 2019-05-24 南阳师范学院 (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
JP2019514862A (ja) 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
WO2019242599A1 (zh) * 2018-06-19 2019-12-26 浙江海正药业股份有限公司 四氢异喹啉类衍生物、其制备方法及其用途
WO2020013951A1 (en) * 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
CN113880825A (zh) 2020-07-01 2022-01-04 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
CN111777555B (zh) * 2020-09-04 2020-12-01 上海赛默罗生物科技有限公司 脂肪环烷衍生物、其制备方法、药物组合物和其应用
CN114315619B (zh) * 2022-01-17 2023-03-24 山东泓瑞医药科技股份公司 一种二甲氧基多巴的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018104B1 (en) * 1979-03-26 1983-05-25 Takeda Chemical Industries, Ltd. Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension
GB2048863B (en) * 1979-05-16 1983-06-15 Morton Norwich Products Inc Tetrahydroisoquinoline-3-carboxylic acids
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
IN156096B (ko) * 1981-03-19 1985-05-11 Usv Pharma Corp
FR2595356B1 (fr) * 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
GB8807922D0 (en) * 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Isoquinoline compound & process for preparation thereof
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders

Also Published As

Publication number Publication date
RU94046067A (ru) 1996-09-27
HU217069B (hu) 1999-11-29
CZ284177B6 (cs) 1998-09-16
HUT70441A (en) 1995-10-30
AU6562396A (en) 1996-11-07
MX9302888A (es) 1993-11-01
NO302071B1 (no) 1998-01-19
SK280677B6 (sk) 2000-06-12
NO944421L (no) 1994-11-18
NO944421D0 (no) 1994-11-18
AU682136B2 (en) 1997-09-18
AU4290693A (en) 1993-12-13
EP0641326A1 (en) 1995-03-08
CZ282894A3 (en) 1995-09-13
US5246943A (en) 1993-09-21
CA2134765A1 (en) 1993-11-25
US5350757A (en) 1994-09-27
SK138594A3 (en) 1995-07-11
RU2135473C1 (ru) 1999-08-27
WO1993023378A1 (en) 1993-11-25
NZ252856A (en) 1997-08-22
HU9403322D0 (en) 1995-02-28
JPH07508266A (ja) 1995-09-14
US5525614A (en) 1996-06-11
US5489686A (en) 1996-02-06
AU671283B2 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
KR950701622A (ko) 안기오텐신 ii 리셉터 안타고니스트 특성을 지니는 치환된 1,2,3,4-테트라하이드로 이소퀴놀린(substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ⅱ receptor antagonist properties)
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
FI904602A0 (fi) Pyrazoloderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
DE69205327D1 (de) Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.
TW224464B (ko)
FI882813A (fi) Pyrazolopyridinfoerening och foerfarande foer dess framstaellning.
LU91112I2 (fr) Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable.
FI933810A (fi) Reseptorantagonister av exiterbara aminosyror
HUP0001154A2 (hu) 3-Piperidil-4-oxo-kinazolin-származékok és a vegyületeket tartalmazó gyógyászati készítmények
DE69505542D1 (de) 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
ATE250573T1 (de) Azetidin- und pyrrolidinderivate
ZA934997B (en) Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives
KR940014313A (ko) 하이드록시아미딘 유도체
EP0391721A3 (en) Ocular hypotensive agents
TW221429B (ko)
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
ATE56967T1 (de) Amidderivate.
DE3764918D1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK0660840T3 (da) Phosphono-substituerede tetrazolderivater.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
SUBM Surrender of laid-open application requested